Literature DB >> 6621025

Delayed-type cutaneous hypersensitivity to Thomsen-Friedenreich (T) antigen in patients with pancreatic cancer.

R L Goodale, G F Springer, J G Shearen, P R Desai, H Tegtmeyer.   

Abstract

The delayed-type hypersensitivity skin reaction to human erythrocyte-derived Thomsen-Friedenreich (T) antigen was studied in 40 patients with pancreatic disease and in 158 control subjects and its sensitivity and specificity were compared with the carcinoembryonic antigen (CEA) blood levels. The skin reaction to T was positive in 22 of 25 patients with biopsy-proven adenocarcinoma of the pancreas (sensitivity, 88%). In these patients, the CEA levels were elevated above 3.5 ng/ml in 12 of 23 (52%). The skin test to T antigen was negative in 11 of 12 patients with chronic pancreatitis (specificity, 92%), but CEA levels were normal in only five of nine with pancreatitis (56%). Two of the patients with pancreatic carcinoma and one of those with pancreatitis were anergic to mumps and dermatophytin antigens and had thus an invalid skin test. The positive response rate to T antigen was significantly greater (P less than 0.005) in the cancer group than the group with pancreatitis; the CEA response was not significantly different. There were no positive responses to T in 82 healthy volunteers. Among 76 patients with chronic disease including six with malignant tumors of the mesoderm and central nervous system, there were four positive responses: two in heavy smokers and two in patients with chronic lung infection. The specificity of the test overall in 158 controls was thus 97.5%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6621025     DOI: 10.1016/0022-4804(83)90004-5

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

Review 1.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

2.  Lung cancer patients' autoimmune responses to Thomsen-Friedenreich (T) antigen: diagnostic utility.

Authors:  W A Fry; G F Springer; P R Desai
Journal:  Klin Wochenschr       Date:  1983-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.